Orexin Neural Activity Associated with Morphine Spontaneous Withdrawal-Induced Anxiety in Rats by Ly, Robin
Connecticut College
Digital Commons @ Connecticut College
Psychology Honors Papers Psychology Department
1-1-2011
Orexin Neural Activity Associated with Morphine
Spontaneous Withdrawal-Induced Anxiety in Rats
Robin Ly
Connecticut College, robin.ly@conncoll.edu
Follow this and additional works at: http://digitalcommons.conncoll.edu/psychhp
This Honors Paper is brought to you for free and open access by the Psychology Department at Digital Commons @ Connecticut College. It has been
accepted for inclusion in Psychology Honors Papers by an authorized administrator of Digital Commons @ Connecticut College. For more
information, please contact bpancier@conncoll.edu.
The views expressed in this paper are solely those of the author.
Recommended Citation
Ly, Robin, "Orexin Neural Activity Associated with Morphine Spontaneous Withdrawal-Induced Anxiety in Rats" (2011). Psychology
Honors Papers. Paper 18.
http://digitalcommons.conncoll.edu/psychhp/18
ORX and EPM 
 
 
 
 
 
 
 
 
Orexin Neural Activity Associated with Morphine Spontaneous Withdrawal-Induced Anxiety in 
Rats 
Robin Ly 
Connecticut College 
May 5, 2011 
 
 
 
 
 
 
 
 
 
 
ORX and EPM   2	  
Table of Contents 
Acknowledgements…………………………………………………………………………….3 
Abstract………………………………………………………………………………………...4 
Introduction…………………………………………………………………………………….5 
Methods………………………………………………………………………………………..40 
Results………………………………………………………………………………………....45 
Discussion……………………………………………………………………………………..47 
References……………………………………………………………………………………..58 
Table 1………………………………………………………………………………………....77 
Figure Captions………………………………………………………………………………..78 
Figure 1………………………………………………………………………………………...80 
Figure 2………………………………………………………………………………………...81 
Figure 3………………………………………………………………………………………...82 
Figure 4………………………………………………………………………………………...83 
Figure 5………………………………………………………………………………………...84 
Figure 6………………………………………………………………………………………...85 
Figure 7………………………………………………………………………………………...86 
Figure 7b……………………………………………………………………………….87  
Figure 7c……………………………………………………………………………….88 
 
 
 
 
ORX and EPM   3	  
Acknowledgements 
 
Research has always been a huge passion of mine, and it wasn’t until having classes like 
PSY 101 as a Natural Science with Dr. Joseph Schroeder and PSY 322 with Dr. Ruth Grahn, 
when I realized what field I wanted to focus my studies in. I would like to specifically thank my 
advisor, Dr. Ruth Grahn whose involvement has been the most critical throughout this whole 
project. Without Professor Grahn’s confidence and guidance, I would not have been able to push 
myself and accomplish the demanding tasks that this project has forced me to confront. I would 
also like to thank my reader Professor Schroeder for his patience with my project.  
Dr. Grahn and Dr. Schroeder, your passion for educating and neuroscience in general has 
transcended upon myself and you have no idea how much of an impact you have made. I look 
around at my peers and I truly believe that my kind passion and curiosity is not evident in many 
students, and a great deal of that passion and curiosity comes from your teaching. 
To my friends and family, I cannot express the endless encouragement and support that 
you have given me from beginning to end. I would like to particularly thank my cousin, my 
“older” sister, Jenny who has always believed that I would never fail, but thrive on this project. 
You have been there through my most stressful times and were always willing to listen even 
though half the time you never understood what I was saying. I would also like to thank Erika 
Clark, who has always believed in my technical skills in the lab when I didn’t have the 
confidence. Erika, you have been an amazing mentor throughout this process and have taught me 
so much more than you know. Thank you everyone again, without you, my confidence in my 
project and myself would not have been possible. 
 
 
ORX and EPM   4	  
Abstract 
 
 Hypocretin, also known as orexin, plays a critical role in maintaining and regulating 
arousal, sleep, and homeostatic functions.  Recently, orexin has shown to influence drug 
addiction neural circuitry, specifically in mediating the hypothalamic response to stress and 
reinstatement of drug seeking behaviors during withdrawal. Thirty-two male Sprague-Dawley 
rats were observed on the elevated plus-maze to examine withdrawal-induced anxiety levels. 
Rats with prior exposure to 6 daily injections of 3mg/kg morphine were compared to saline-
treated animals.  C-Fos and orexin immunohistochemistry was used to examine lateral 
hypothalamic (LH) activity as well. There was a statistically significant difference in c-
Fos/orexin double-labeled cells between groups, which suggests that orexinergic neurons were 
activated during spontaneous withdrawal from morphine after being subjected to the elevated 
plus-maze (EPM). There were no other significant differences found, however general trends 
were observed in open-arm duration between groups and c-Fos activation. Future studies should 
incorporate the manipulation of the orexin neural system during induced-spontaneous withdrawal 
with the orexin antagonist SB334867. 
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Orexin Neural Activity Associated with Morphine Spontaneous Withdrawal-Induced Anxiety in 
Rats 
There are times in all of our lives when the desire for natural rewards, such as food and 
sex, strongly motivates our behavior. Although the diagnostic criteria of addiction do not 
typically apply to seeking food and sex, the neuronal circuitry for natural rewards to motivate 
behavior is hypothesized to be the same circuitry activated by addictive drugs to reinforce and 
produce addiction. For example, neuroimaging studies have shown that cues associated with both 
drugs of abuse and natural rewards activate overlapping cortical and limbic circuitry (Sharf, 
Sharhan & DiLeone, 2010).  
Drug addiction is a chronically relapsing disorder that is defined by two major 
characteristics: a compulsion to take the drug with a narrowing of the behavioral repertoire 
toward excessive drug intake, and a loss of control in limiting intake (American Psychiatric 
Association 1994; World Health Organization 1992). The most problematic drugs are alcohol, 
nicotine from tobacco, and opioids.  About 18 million Americans abuse or are dependent on 
alcohol with 2.2 million people, approximately 10% currently seeking treatment. The cost to 
society for alcohol abuse is estimated at $185 billion per year. In the US, approximately 440,000 
persons die per year from cigarette smoking. Cigarette smoking causes about $75 billion in direct 
medical costs. Opioid dependency has also been growing rapidly, especially from 1990 to 2001. 
The number of people who used prescription painkillers recreationally for the first time grew 
335%, which includes almost 2.5 million people (Koob & Le Moal 2000).   
Illicit drug use in the United States has risen to its highest level in 8 years, according to 
the 2009 National Survey on Drug Use and Health (NSDUH). Last year, 8.7 percent of 
Americans that were 12 years and older said they used illegal drugs in the month prior to the 
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survey. This represents a 9 percent increase or 21.8 million people over the 2008 rate. Addicts 
continually crave more and more drug, as its effects captivate them. The structure and function 
of the brain are changed with repeated use. Consequently, over time the act of using drugs is no 
longer voluntary and no longer for pleasure. Addicts often self-medicate to feel “good” or feel 
“normal” (NIDA 2009).  
Drug addiction is not a physiological dysregulation that can be explained by a single 
component, but rather by different components that interplay to create a cycle (Baumeister, 
Heatherton & Tice 1994). The addiction cycle has been described as having three factors: 
preoccupation-anticipation, binge-intoxication and withdrawal-negative affect (Koob & Le Moal 
1997). Behaviorally, spiraling distress occurs and builds a negative affect when there is a failure 
to self regulate (Baumeister, Heatherton & Tice 1994).  The focus on the pleasurable effects of 
taking the drug leads to greater and greater use, with increasing intoxication and negative 
consequences of drug use.  At this point the effort to control intake is made difficult by 
withdrawal symptoms, leading to continued use of the drug and more and more negative feelings 
about being addicted.   
Spiraling distress can also be described as a progressive dysregulation of the brain reward 
system within the context of repeated addiction cycles.  While this dysregulation is difficult to 
study in humans, there are animal models that have been validated for different symptoms or 
constructs associated with elements of the addiction cycle, addiction criteria and sources of 
reinforcement associated with addiction (Koob & Le Moal 1997). 
 The addiction cycle is also composed of multiple sources of positive and negative 
reinforcements that can contribute to compulsivity for drug use. Positive reinforcement, in the 
context of reward is often associated with pleasurable effects of drugs in the absence of a 
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deprived or distress state. For example, pleasurable components of drug addiction include the 
presence of the drug and the ability to use the drug and achieve a high. Positive reinforcement 
also occurs when the sight of the drug at its receptor increases the addict’s craving, increasing 
the probability of taking the drug again. Secondary positive reinforcement is when there is a 
conditioned pairing of previously neutral stimuli with acute positive reinforcing effects. In 
contrast, negative reinforcement occurs with alleviation of an existing aversive state or of 
withdrawal (Koob & Le Moal 2001). Secondary negative reinforcing effects occurs with the 
removal of the conditioned negative reinforcing effects of conditioned abstinence. Conditioned 
positive and negative reinforcement generally contributes to the preoccupation and anticipation 
stage of the drug addiction cycle (Baumeister, Heatherton & Tice 1994). The neurobiological 
basis for acute positive reinforcing effects of drugs of abuse, negative reinforcing effects 
imparted by the dependent state and the conditioned reinforcing effects associated with 
protracted abstinence and relapse have provided insight into the basis of addiction. Protracted 
abstinence is defined as a state of residual reward dysregulation after acute withdrawal (Koob & 
Le Moal 2000). 
Drug addiction, or substance dependence has been hypothesized to occur when there is a 
detachment from homeostatic brain regulatory mechanisms that control normal everyday 
emotional states (Sharf, Sharhan & DiLeone 2010). Specifically, two factors have been 
hypothesized to comprise the break from homeostasis, the under-activation of brain reward 
neurotransmitters and the recruitment of brain stress systems. The reward and stress systems all 
interact at different stages of the addiction cycle to potentiate the dysregulation (Edwards & 
Koob 2010). Similar to chronic physiological disorders, the effects worsen over time and are 
subject to significant environmental influences and leave a lasting neuroadaptive trace that 
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allows rapid reinstatement of addictive behaviors even years after detoxification and abstinence. 
However, the characteristics of drug addiction are more than just a homeostatic dysregulation of 
hedonic function and executive function, rather a dynamic break with homeostasis of these 
systems toward a new set point, often noted as allostasis (Volkow, Fowler, Wang & Swanson 
2004). 
Allostasis was originally conceptualized to explain the persistent illness of arousal and 
autonomic function associated with chronic stress. Allostasis is defined as ‘stability through 
change’ in which continuous readjustment of physiological mechanisms occurs toward a new 
state (McEwen 2000). The state of chronic regulatory system abnormality from its normal or 
homeostatic operating level can be defined as an ‘allostatic state.’ Two components of the brain 
are hypothesized to adjust to the challenges imposed by drugs of abuse to produce an allostatic-
like state: under-activation of reward circuitry and activation of the stress response (McEwen 
2000). Repeated challenges, such as drugs of abuse, lead to attempts of the brain via 
biochemical, cellular and neurocircuitry changes to maintain stability. For drug addiction, the 
residual deviation from normal brain reward threshold regulation is termed an ‘allostatic state’, 
and the cost leading to sustained pathology is the ‘allostatic load.’ The allostatic state represents 
motivational perception by decreased function of reward circuits and recruitment of brain stress 
systems, which lead to the compulsivity of drug seeking and drug taking to prevent withdrawal-
like symptoms. 
Drug addiction is a chronically relapsing disorder characterized by: compulsion to seek 
and take drugs, loss of control in limiting intake, and emergence of a negative emotional state 
reflecting motivational withdrawal syndrome when the drug is not available (Koob 2009). 
Addiction has been signified as an evolving disorder with three stages; anticipation or 
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impulsivity, bing/intoxication, and withdrawal/negative affect. When a drug addict moves 
through these stages, from positive reinforcement driving the motivated behavior to negative 
reinforcement driving the motivated behavior, removal of the aversive stimulus will increase the 
probability of a response (Koob & Le Moal 2004). As a commonality, all drugs produce this 
psychological cycle but different drugs produce different patterns of addiction with different 
components of the addiction cycle (Koob 2009).  
Neuropharmacological studies have shown the importance of the mesolimbic system and 
its role in reward, specifically the release of dopamine from the ventral tegmental area or the 
“pleasure center.” The midbrain dopamine system is composed of two major projections: the 
nigrostriatal system which projects from the substantia nigra to the corpus striatum and the 
mesocorticolimbic dopamine system which projects from the ventral tegmental area (VTA) to 
the nucleus accumbens (Koob, Sanna & Bloom 1998). The mesocorticolimbic system has been 
primarily implicated as mediating the reinforcing actions of drugs of abuse. For example, 
psychostimulants such as cocaine increase the extracellular concentrations of dopamine by 
inhibiting the reuptake by the dopamine transporter. The dopamine system can be modulated by 
endogenous opioids like endorphins, enkephalins and dynorphin, which the body naturally 
produces. Endogenous opioids have a wide range of functions like regulating reactions to pain 
and vital functions such as hunger and thirst, mood control, immune response and other 
processes. One of the main reasons why opiates such as heroin and morphine affect the brain so 
powerfully is the ability of the exogenous substances to bind to the same receptors as the 
endogenous opioids. There are three kinds of opioid receptors that are found distributed 
throughout the brain; mu, delta, and kappa receptors. The receptors are G-protein coupled, 
functioning via second messengers and can influence the opening of ion channels.  
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In many cases the opening of the ion channels reduces the excitability of neurons and the 
reduction is thought to be the reason for the euphoric effect of opiates that bind to mu and delta 
receptors. The GABA inhibitory interneurons of the VTA are also involved in the euphoric 
effect. When exogenous opioids, like morphine bind to the mu receptors, the effect decreases the 
amount of GABA released into the synapse. When there is no morphine, GABA usually reduces 
the amount of dopamine release in the nucleus accumbens. However, with morphine or any other 
opiate present, the result is inhibiting the inhibitor, which ultimately increases dopamine levels 
and the amount of pleasure felt.  
The development of addiction and vulnerability to relapse following withdrawal is 
proposed to be the result of neuroadaptive processes within the central nervous system that 
oppose the acute reinforcing actions of drugs of abuse (Weiss et al., 2006). These changes lead to 
impairment in the mechanisms that mediate positive reinforcement and the emergence of 
affective changes such as anxiety, dysphoria, and depression during withdrawal. Considerable 
evidence exists implicating perturbations in DA and 5-HT transmission in the nucleus 
accumbens—neurochemical systems that are activated by cocaine and ethanol self-
administration and are deficient during withdrawal—as potential substrates for these affective 
changes (Logrip, Koob & Zorrilla 2011, Weiss 2006). 
One component of the cycle of drug addiction is the transitional development of aversive 
or negative emotional states during the allostatic load. Negative emotional states consist of 
certain motivation elements such as irritability, emotional pain, dysphoria and loss of motivation 
for natural rewards (Edwards & Koob 2010, Weiss et al., 2006). Two clear processes that have 
been hypothesized to play an active role in the neurological basis of this state: loss of function in 
the reward systems and hyperactivity of brain stress systems (Volkow, Fowler, Wang & 
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Swanson 2004). Growing evidence suggests that enhanced CRF release in the central nucleus of 
the amygdala represents a mechanism underlying the anxiogenic and stress-like consequences of 
withdrawal that are common to all drugs of abuse. A growing body of evidence implicates 
dysregulation of this non-neuroendocrine CRF stress system as a common factor in the 
anxiogenic and aversive consequences of withdrawal from drugs of abuse (Weiss et al., 2006). 
Stress can be defined generally as responses to demands upon the body or, specifically on 
the central nervous system, as alterations in psychological homeostatic processes (Hennessey & 
Levine 1979). A state of stress is associated with various external and internal challenges to the 
body and brain, usually termed stressors, and the construct of stress may represent the extreme 
pathological continuum of over-activation of the normal activation (arousal) or emotional 
systems of the body. The state of stress is reflected biologically by various physiological changes 
that include an activation of the pituitary-adrenal axis and release of glucocorticoids into the 
bloodstream, activation of the sympathetic nervous system, and activation of brain emotional 
systems (Koob & Le Moal 2000). The hypothalamic-pituitary adrenal axis is the center and the 
stress regulatory system of an organism that connects the central nervous system with the 
hormonal system. Cortisol, which is released at the end of the chain, has a wide range of 
physiological effects in the body. Cortisol plays a critical role in metabolism by mobilizing 
resources to provide energy. The release of cortisol increases metabolic demands presented by 
the stressor and allows the organism to adapt and also maintain homeostasis and support normal 
physiological functioning (Kudielka & Kirschbaum 2005). 
When an organism is presented with a stressor, the hypothalamus secretes corticotrophin-
releasing hormone (CRH), which produces the release of adrenocorticotropic hormone (ACTH) 
from the pituitary. ACTH then triggers the secretion of glucocorticoids from the adrenal cortex. 
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In humans, the main glucocorticoid is cortisol, which is predominately bound to proteins in 
blood and about 5-10% of total plasma cortisol circulating as biologically active or “free” 
cortisol (Kudielka & Kirschbaum 2005). Normally, high levels of glucocorticoids, via negative 
feedback decrease CRF synthesis at the level of the paraventricular nucleus but activate CRF 
activity at the level of the central nucleus of the amygdala. Stressful stimuli also activate CRF 
systems in the basal forebrain, particularly the bed nucleus of the stria terminalis and the central 
nucleus of the amygdala to help mediate behavioral responses to stressors and to mediate 
sympathetic activation associated with stressors systems (Koob & Le Moal 2000). 
Glucocorticoids, instead of exerting a feedback suppression of CRF synthesis in the central 
nucleus of the amygdala, actually increase synthesis of CRF providing a means for extending the 
contribution of the brain stress systems to allostasis (Kudielka & Kirschbaum 2005). 
Stress has been hypothesized as a state that contributes tremendously to different stage of 
the addiction cycle. Specifically, the focus of stress on addiction has been associated with 
withdrawal or the negative affect stage (Koob & Le Moal 1997). The role of CRF as a 
component of addiction cycle is based on the opponent process theory, which has been expanded 
into the different domains of the neurobiology of drug addiction from a neurocircuitry 
perspective. An allostatic model of the motivational systems has been proposed to explain the 
changes of motivation that are associated with the dependence in addiction (Koob & Le Moal 
2001). This view conceptualizes addiction as a cycle of increasing dysregulation of brain 
reward/anti-reward mechanisms that results in a negative emotional state, which strengthens 
compulsive drug use. Counteradaptive processes that are normally part of homeostatic limitation 
of reward function fail to revert back to normal homeostatic range. The counteradaptive 
processes are hypothesized to be mediated by two mechanisms: within-system, which is changes 
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in the reward pathways and between-systems neuroadaptations, which is the recruitment of the 
brain stress systems (Koob & Bloom 1988). The recruitment of the brain stress systems where 
CRF most likely a significant component of the negative reinforcement processes that drive the 
compulsivity of drug addiction (Koob 2009). The opponent process theory assumes that many 
affective states, whether pleasant or aversive are automatically opposed by centrally mediated 
mechanisms that reduce the intensity of the affective state (Koob, Markou, Weiss & Shulteis 
1993). The opponent process theory hypothesizes that positive reinforcers, like drugs have 
positive hedonic processes that are counteracted by negative hedonic processes (Koob & Le 
Moal 2008).  
Positive hedonic processes are hypothesized to be stable and simple with a short latency 
and duration and follow right after drug administration. Negative hedonic processes have longer 
latencies and build up on strength and diminish slowly and resistant to the development of 
tolerance (Koob, Markou, Weiss & Shulteis 1993).  The example of an opiate “rush” is 
considered a positive hedonic process and the withdrawal symptoms are a reflection of opponent 
negative hedonic processes. Self-administration of drugs of abuse have tolerance to euphoric 
effects while at the same time the withdrawal or abstinence of the drug becomes more intense 
and of longer duration. The positive reinforcing properties slowly diminish while the negative 
reinforcing properties strengthen. Specific brain areas that are involved in reward and stress 
within the basal forebrain like the ventral striatum and amygdala are thought to be dysregulated 
in addiction. These structures convey the opponent motivational processes that drive dependence 
in addiction. Neurotransmission in these structures are not only experiencing a decrease in 
reward neurotransmission from dopamine and opioid peptides in the ventral striatum but there is 
also a recruitment of brain stress systems such as corticotropin-releasing factor, noradrenaline 
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and dynorphin in the amygdala (Koob 2009). From a social psychological standpoint, stress 
contributes to the addiction process known as under regulation such as decreases in strength and 
sources of misuse such as self-medication, leading to spiraling distress (Baumeister, Heatherton, 
Tice 1994). From a psychiatric perspective stress is the major state or stimulus associated with 
vulnerability to relapse (Erb, Shaham & Stewart 1996).  
As addiction progresses, the brain’s stress system releases corticotropin-releasing factor 
(CRF), norepinephrine and dynorphin at higher rates which produce aversive or stress-like 
behavior. At the same time, the mesolimbic system, which drives positive motivation and reward 
that was associated with the initial use of the drug, declines (Edward & Koob 2010). 
Consequently, the negative emotional state develops with chronic use, and drugs are 
subsequently taken to alleviate negative motivational symptoms associated with withdrawal. 
The release of corticotropin-releasing factor or CRF during stress is an unavoidable 
consequence of daily experiences that occur from external environmental stimuli. Therefore the 
release of CRF or cortisol affects a wide range of critical physiological processes. The body must 
strictly regulate the activity of the stress response because of the wide range of external stressors. 
The role of stress during addiction is often recognized during withdrawal or drug-seeking 
behaviors. Acute withdrawal from addictive drugs has been associated with physical signs that 
vary depending on the drug of abuse. Recent conceptualizations of addiction have considered 
that the physical signs of withdrawal serve as only one of the symptoms associated with 
addiction (Erb, Shaham & Stewart 1996). However, other variables contribute to acute 
withdrawal that have motivational significance into the cycle of drug addiction; these actions fall 
under the conceptual framework of stress. 
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Acute withdrawal is associated with a negative affective state, which includes dysphoria, 
depression, irritability and anxiety. For example, cocaine withdrawal in humans is characterized 
by severe depressive symptoms as well as irritability, anxiety and anhedonia, which can last 
several hours to days. These symptoms are associated with the motivating factors in the 
maintenance of cocaine dependence (Gawin & Kieber 1986). Opiate and ethanol withdrawal 
produce dysphoria. It has been suggested that the motivational effects of drug withdrawal may 
have the same neural substrates and neuropharmacological mechanisms of the neural systems for 
the positive reinforcing effects of drug abuse. For example, when intracranial self-stimulation 
was used to measure reward thresholds throughout the course of drug dependence, the results 
showed that reward thresholds increased following chronic administration of major drugs of 
abuse such as opiates, psychostimulants, ethanol, and nicotine. The effects appeared to reflect 
changes in the activity of the same mesocorticolimbic system known for its neural positive 
reinforcing effects of drugs and can last up to 72 hours depending on the drug and dosage (Koob 
2006). 
Neuroadaptive mechanisms that are associated with reward function have been 
hypothesized to be neurochemical changes associated with the same neurotransmitters implicated 
in the acute reinforcing effects of drugs (Koob & Bloom 1988). When measured by in vivo 
microdialysis, an example of homeostatic within-system adaptive neurochemical events would 
include decreases in dopaminergic and serotonergic neurotransmission in the nucleus accumbens 
during drug withdrawal (Parsons, Koob & Weiss 1995 and Weiss, Markou, Lorang & Koob 
1992). Increased sensitivity of opioid receptor transduction mechanisms in the nucleus 
accumbens has been shown during opiate withdrawal and decreased GABAergic and increased 
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NMDA glutamatergic transmission has been shown during ethanol withdrawal (Stinus, Le Moal 
& Koob 1990).  
Additional evidence supporting a role for brain stress systems being activated during 
acute withdrawal are studies showing an increase in extracellular levels of CRF in the region of 
the central nucleus of the amygdala during acute withdrawal from drugs of abuse. Animals 
exposed to a chronic ethanol liquid diet to induce ethanol dependence showed a time-related 
increase in CRF in the amygdala as measured by in vivo microdialysis (Merio-Pich et al., 1995). 
Similar results have been observed during withdrawal from cocaine (Richter & Weiss 1999) and 
precipitated cannabinoid withdrawal (Rodrigues De Fonseca, Carrera, Navarro, Koob & Weiss 
1997). 
Animal models of symptoms of addiction on specific drugs such as stimulants, opioids, 
alcohol and nicotine have been used to define the different stages of the addiction cycle 
(Shippenberg & Koob 2002). For example, animal models focused on the binge/intoxication 
stage of addiction can be conceptualized as measuring acute drug reward where the reward is a 
positive reinforcer with additional emotional value. Animal models associated with 
withdrawal/negative affect stage have used conditioned place aversion to precipitated withdrawal 
or spontaneous withdrawal thresholds and dependence-induced increases drug seeking (Koob 
2008). Furthermore, chronic administration of drugs has been known to cause a dysregulation of 
the stress responses mediated by CRF not only by the HPA axis but also the brain extra 
hypothalamic stress system (Koob 2009). In general, a stress response to all drugs of abuse and 
alcohol and acute withdrawal cause an activated HPA response. However, with chronic usage of 
drugs of abuse, there is a blunted HPA response but also a sensitized extra hypothalamic CRF 
stress system response (Koob & Kreek 2007).  
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In vivo microdialysis during acute withdrawal following chronic administration or self-
administration of drugs of abuse have been shown to produce an increase in extracellular CRF in 
the extended amygdala (Merio-Pich et al. 1995). During alcohol withdrawal, hyperactivity of the 
extra hypothalamic CRF systems are combined with an increase in extracellular CRF within the 
central nucleus of the amygdala and bed nucleus of the stria terminalis of dependent rats (Merio-
Pich et al. 1995; Olive et al. 2002). Extracellular CRF was also increased in the central amygdala 
during precipitated withdrawal from chronic nicotine (George et al. 2007), binge cocaine self-
administration (Richter & Weiss 1999), and precipitated withdrawal from opioids (Weiss et al., 
2001) and cannabinoids (Rodriguez de Fonseca et al. 1997).  
Another common response to acute withdrawal from major drugs of abuse is the 
manifestation of negative emotional state, including anxiety-like responses. There have been 
animal models in which the dependent variable is commonly a passive response to a novel or 
aversive stimulus; such as the open field test, elevated plus-maze, defensive withdrawal test or 
social interaction test; or an active response to an aversive stimulus, such as defensive burying 
which have shown anxiety like responses to acute withdrawal from all major drugs of abuse. 
When subjected to repeated exposure and then withdrawal of cocaine, alcohol, nicotine, 
cannabinoids, and benzodiazepines, they produce anxiogenic-like responses in the elevated plus-
maze, defensive withdrawal or defensive burying test. Furthermore, the effects can be reversed 
by using CRF antagonists (Rodriguez de Fonseca et al. 1997; Basso et al, 1999; Knapp et al. 
2004; George et al. 2007). 
Elevated-plus maze and Drug Withdrawal 
The elevated plus-maze (EPM) has been used to study anxiety-related behavior in rodents 
(Pellow, Chopin, File & Brilley 1985) and assessing the anti-anxiety effects of pharmacological 
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agents that are known to produce anxiolytic effects such as chlordiazepoxide and diazepam and 
ones that cause anxiety such as yohimbine, caffeine and amphetamines (Pellow, Chopin, File & 
Brilley 1985) and steroid hormones (Walf & Frye, 2007), defining brain regions and mechanisms 
underlying anxiety-related behavior (Pellow, Chopin, File & Brilley 1985; Hogg 1996; Walf & 
Frye 2007). The behaviors that are commonly recorded when using the elevated plus maze are 
the time spent and entries made on open and closed arms (Pellow, Chopin, File & Brilley 1985; 
Walf & Frye 2007). The EPM consists of two open and two closed arms with a central exposed 
area where the arms bisect each other (Pellow, Chopin, File & Brilley 1985; Paterson, Iwunze, 
Davis, Malekiani Hanania 2010). Activity in the open arms is considered to be a conflict 
between the rodent’s preference for protected areas or closed arms that would be considered their 
innate motivation to explore novel environments. Anti-anxiety behavior which would produce an 
increase time on the open arm or open arm entries can be determined with a measure of 
spontaneous motor activity, total and/or closed arm entries. Other ethological measures can also 
be observed like the number of rears, freezing stretched-attend postures, protected and 
unprotected head dips, grooming or sniff duration (Rodgers & Johnson 1995).  
Normal exploratory behavior in the elevated plus-maze is usually in favor of the closed 
arms and this tendency to stay in the closed aspects of the maze can be enhanced by drugs like 
anxiogenics that increase the aversion towards the anxiety-provoking open arms. In contrast, 
when subjects are administered anxiolytic compounds, the behaviors produced will reduce 
natural aversion to the open arms and promote the exploration. The critical aspect of the EPM is 
the number of entries made onto the open arm and time spent on the arms. These variables have 
been correlated with anxiety (Hogg 1996). Locomotor activity is assessed by monitoring the total 
or closed number of arm entries (File 1992; Lister 1987).  
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The elevated plus-maze has frequently been used in research as a tool to measure anxiety-
like behaviors during withdrawal. Subjects who have been repeatedly exposed to drugs of abuse 
are hypothesized to exhibit withdrawal-like symptoms like drug-seeking behavior. Drug-seeking 
behavior has been generally characterized as the subject more likely spending time in the closed 
arms compared to the open arms in the elevated plus-maze. 
 In recent studies, in evaluating withdrawal from chronic exposure to ethanol, the 
elevated plus-maze has been used to study anxiety-like behaviors and the underlying 
neurobiology of withdrawal (Taksande et al. 2010) with a decrease in open arm time and percent 
open arm entries (Jung, Wallis, Gatch & Lal 2000). In general, ethanol withdrawal decreases 
most of a subject’s behavior in the EPM, indicating the occurrence of an anxiogenic-like effect 
of withdrawal in rodents, although the effects of withdrawal have not always been consistent 
(Klithermes 2004). However, others argue that the elevated plus-maze experiments using ethanol 
dependent rats have generally been more consistent in finding presumed anxiogenic-like effects 
of ethanol withdrawal with most studies observing increased anxiety like behaviors after the 
cessation of ethanol administration (Baldwin, Rassnick, Rivier, Koob & Britton 1991; Cagetti, 
Liang, Spigelman & Olsen 2003; File, Andrews, al-Farhan 1993). 
Taksande et al (2010) demonstrated the effects of agmatine on acute ethanol anxiolytics 
and withdrawal anxiety in rats using the EPM. Consistent with previous research, acute 
administration of ethanol produced a dose-dependent anxiolytic effect where there was an 
increased percent time spent and entries into the open arms without any changes in the closed-
arm entries. However, animals treated with higher dose (2.5 g/kg, i.p.) of ethanol showed 
decrease in open as well as closed-arm activity in the EPM test, indicating mild sedation or 
motor incoordination as previously reported. When rats were assessed in the EPM 18h following 
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ethanol injections, adult rats showed higher anxiogenic effects of acute withdrawal in the 
elevated plus-maze. The anxiogenic effects were measured as a reduction in percent of open arm 
entries and open arm time, coupled with increases in percent of protected head dips and stretch 
attend postures (Doremus, Brunell, Varlinskaya, Patia Spear 2003). 
The withdrawal symptoms of hyperactivity to external stimuli and increased anxiety-
related behavior in the elevated plus-maze were observed in long-term, voluntary alcohol-
drinking rats with frequent deprivation sessions, (Holter, Linthorst, Reul & Spanagel 2000; Jung, 
Wallis, Gatch & Lal 2000). Furthermore, Holter, Linthorst, Reul & Spanagel (2000) found that 
rats with repeated alcohol deprivation compared to rats without prior alcohol deprivation 
experience exhibited higher anxiety-related behaviors in the EPM. Researchers suggested that 
the blood alcohol levels attained, length of chronic alcohol intake and withdrawal experience 
may have played a role for the intensity of the withdrawal symptoms. 
Addiction to nicotine has also been paired with subsequent addiction to ethanol, 
especially during adolescence. Smokers consume twice as much alcohol as do nonsmokers and 
alcoholics who smoke consume more cigarettes than do nonalcoholic smokers (Larsson & Engel 
2004). Exploratory use of alcohol occurs typically during adolescence and there has been a 
strong correlation between the onset of tobacco consumption at an early age and alcohol 
addiction (Grant 1998).  In a recent study, the elevated plus-maze was used to assess short-term 
and long-term anxiety effects of nicotine and/or ethanol exposure in mice. Researchers found 
that ethanol was anxiolytic in adolescent mice and that nicotine reversed the effect. Short-term 
drug withdrawal elicited sex-dependent effects and exposure to nicotine and/or ethanol was only 
significant in females. Co-administration of ethanol and nicotine also elicited an anxiogenic 
response, which suggested that the deficient response to the anxiolytic effects of ethanol in 
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adolescents co-exposed to nicotine might drive higher ethanol consumption. Furthermore, 
increased anxiety during long-term nicotine and/or ethanol withdrawal may facilitate relapse to 
drug use (Abreu-Villaca, Nunes, Queiro-Gomes, Manahaes & Filgueiras 2008). 
Another study examining the co-consumption of nicotine and ethanol in mice looked at 
withdrawal symptoms during abstinence using the EPM. Researchers observed aversion to the 
open arms of the elevated plus-maze and the modification of spontaneous locomotor activity 
during and following repeated ethanol and/or nicotine administration in mice. Onaivi, Todd & 
Martin (1989) found that ethanol plus nicotine treated animals increased time spent in the open 
arms of the maze during treatment relative to controls. When mice were subjected to 
spontaneous withdrawal, there was a rapid onset of intense aversion to the open arms of the maze 
and a concomitant reduction in locomotor activity that was greater compared to mice subjected 
to spontaneous nicotine and/or ethanol withdrawal alone. The study suggested that the combined 
effects of ethanol and nicotine reduced aversion to the open arms of the elevated plus-maze and 
may imply an anti-aversive action; however mice also demonstrate an increased aversiveness to 
the open arms following spontaneous withdrawal of the both nicotine and ethanol together. 
Studies concerning the acute and chronic effects of nicotine on the elevated plus-maze in 
mice have also been a focus in examining anxiety-related symptoms. Biala and Budzynska  
(2006) examined the effects of nicotine when administered at certain time-points before the mice 
were subjected to the EPM, 5 minutes after an injection, nicotine had an anxiogenic effect by 
causing decreases in the percentage of time spent on the open arms and in the percentage of time 
in open arm entries. Furthermore, after six days of injections, tolerance was observed and on the 
seventh day of injection, an anxiolytic effect was seen with increases in time spent on the open 
arms and percentage of open arm entries. 
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In a separate study, Manhaes, Guthierrez, Filqueiras & Abreu-Villaca (2008) examined 
the anxiety effects of nicotine withdrawal using the EPM in rats. Researchers also tested if 
nicotine consumption could be predicted after being subjected to the elevated plus-maze as a 
model of relapse. Animals were classified as having low anxiety or high anxiety after nicotine 
withdrawal and immediately after finishing exposure to the EPM, rats were given the free choice 
between bottles of water or a nicotine solution. Researchers found that nicotine consumption was 
dependent on the anxiety level where the high anxiety group had lower nicotine consumption 
than other groups. This study suggested that anxiety-like behavior during nicotine withdrawal is 
associated with subsequent nicotine self-administration. 
Other studies examining cocaine withdrawal, demonstrated that rats that are exposed to 
chronic administration of cocaine and then one-day withdrawal found an increase in anxiety-like 
behavior from decreases in delta opioid receptor signaling using the elevated plus-maze. 
Researchers also found depression-like behaviors using the forced swim test. The results of the 
study found that with early withdrawal from cocaine, there is an apparent increase in anxiety and 
depression, which is related to the desensitization of delta opioid receptor function (Perrine, 
Sheikh, Nwaneshiudu, Schroeder and Unterwald 2008). A similar study using the elevated plus-
maze and forced swim test found that after chronic cocaine administration, withdrawal from 
cocaine resulted in a decrease in time spent in the open arms and entries onto the open arms of 
the plus maze. They also observed a reduction in escape behaviors and time to first immobility in 
the forced swim test. However, when researchers administered the nicotinic acetylcholine 
receptor antagonist bis- (2,2,6,6-tetramethil-4-piperidinyl sebacate (BTMPS), cocaine-induced 
anxiety-like behaviors were reversed in the elevated plus-maze as were depressive-like behaviors 
in the forced swim test (Hall, Pearson, Buccafusco 2010). 
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 Sorge and Stewart (2005) presented the importance of studying responses during late 
withdrawal where stressor-induced reinstatement is lower during early withdrawal when 
“anxiety” responses are most pronounced and is heightened later during withdrawal when 
“anxiety” responses are likely diminished. In order to investigate anxiety-like behaviors in 
repeated cocaine administration and withdrawal, Mantsch, Baker, Francis, Katz, Hoks & Serge 
2007) examined stress-related responses further into withdrawal. Researchers found that rats that 
had a shorter exposure to cocaine had an increased activity in the elevated plus-maze. Several 
weeks after extinction/withdrawal, rats that had a shorter exposure to cocaine still had more 
activity during times of stress associated with heightened susceptibility to stressor-induced drug-
seeking behavior, which may be the result of increases in CRF regulation. 
In a separate study Huang, Liu-Chen and Kirby (2010) attempted to characterize the 
emotional aspects of SR141716-precipitated THC withdrawal in a mouse model of anxiety using 
the EPM and found a reduction in the percent of open arm exploration compared to vehicle. 
Marijuana discontinuation has been characterized as anxiogenic; therefore researchers were the 
first to explore the potential anxiogenic effects of precipitated THC withdrawal. Researchers 
concluded that the decrease in open arm entries was a result of anxiety-like behavior whereas 
Pellow, Chopin, File & Brilley 1985 described decreases in open arm entries were indicative of 
anxiety-like behavior. The experimental design was novel, insofar that the conclusions made by 
the researchers were dependent on the levels of CRF in mice that were subjected to precipitated 
THC withdrawal and EPM. Mice treated with SR141716 precipitated a reduction in exploration 
of the open arms of EPM in mice repeatedly treated with THC vs. vehicle. SR141716 
significantly reduced the percent of open arm entries per of the total arm entries and open arm 
time of total time in arms. This was the first evidence that cannabinoid withdrawal produces 
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anxiety-like effects in mice. This animal model may help to identify the mechanisms that 
contribute to adaptations in the neuronal circuitry of the brain that are expressed as emotional 
symptoms of cannabinoid withdrawal.  
Similar to the previous studies, Zhang and Schulteis (2008) used morphine and found that 
withdrawal from acute morphine at low doses can produce anxiolytic effects with increased 
exploration in open arm entries. Researchers also found that repeated administration of morphine 
resulted in a further increase in the magnitude and duration of this anxiolytic-like effect. Three 
injection regimens were employed: Morphine Naive four vehicle injections, Acute Morphine 
with three vehicle injections and the fourth injection of morphine, or Repeat Morphine with four 
injections of morphine. Acute pretreatment with morphine resulted in time-dependent increases 
in exploration of the open arms of the plus maze in naloxone-naive rats when tested at 2, 4 or 8 
hr. after the final pretreatment injection, with the effects at the higher dose appearing later four 
hours later than after the lower dose 2 hr. This pattern of results confirms a significant 
anxiolytic-like effect of a low dose of morphine 0.56 mg/kg administered 15 min prior to test, 
suggested that low residual morphine levels remaining in plasma at 2-4 hr. after 5.6 and 10 
mg/kg morphine may be sufficient to elicit anxiolytic-like effects. Repeat treatment with either 
dose of morphine resulted in a further increase in the magnitude and duration of this anxiolytic-
like effect. These effects had dissipated by 8 hr. post-morphine, and therefore precipitation of 
withdrawal by one of several doses of naloxone (0.10-3.3 mg/kg) was assessed in separate 
cohorts of rats 8 hr. after the final pretreatment under Morphine Naïve, Acute Morphine, or 
Repeat Morphine conditions. Naloxone resulted in a significant dose-dependent expression of 
anxiety-like behavior with no effects on general activity after Acute Morphine pretreatment at 
either 5.6 or 10-mg/kg morphine. A further significant shift in naloxone potency was observed 
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after Repeat Morphine pretreatment at the 10 mg/kg but not the 5.6 mg/kg dose. Thus, anxiety-
like behavior is a prominent feature of the negative emotional consequences of naloxone-
precipitated withdrawal from acute opioid dependence. 
Another study examining mice undergoing naloxone-precipitated morphine withdrawal, 
showed behaviors in the elevated plus-maze that were very similar as described in the previous 
study (Buckman, Hodgson, Hofford and Eitan 2009). Mice exhibited an increase in time spent in 
the open arms compared to controls, therefore researchers wanted to further inspect the effect of 
spontaneous morphine withdrawal on the EPM behavior of mice in order to see if increase in 
open-arm time is classically understood to represent an anxiolytic response.  
Researchers found that mice undergoing opioid withdrawal exhibited an increase in EPM 
open-arm time. Buckman, Hodgson, Hofford and Eitan (2009) reported in mice undergoing both 
naloxone-precipitated and spontaneous opioid withdrawal exhibited an unexpected outcome 
where there was an increase time and entries on the elevated plus-maze on the open arm 
compared to controls. Classically, conditions that decrease the amount of time spent in the open 
arms of the EPM are associated with anxiety, while increases in open-arm time are associated 
with an anxiolytic profile. Although an unexpected behavior, since opioid withdrawal is 
associated with increase in anxiety and known to cause negative symptoms including aversion 
and increased plasma CRF levels, the results of the study raise the possibility that perhaps the 
behavioral response in the EPM might be susceptible to modulation by multiple variables and not 
exclusively anxiety. Buckman, Hodgson, Hofford and Eitan (2009) also demonstrated 
that mice exhibited an increase in both open-arm time and percent of open-arm entries 8-hr 
following the last dose of morphine. The increase in open-arm time during withdrawal was not 
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simply due to an overall increase in total activity, since the amount of exploratory activity did 
not change significantly during withdrawal. 
Opioid withdrawal has been recognized as anxiogenic in humans and the elevated plus-
maze has also been used to demonstrate anxiogenic effects in mice. Hodgson, Hofford, Norris & 
Eitan (2008), characterized EPM behaviors of mice during naloxone-precipitated morphine 
withdrawal where naloxone did not show an effect in EPM behaviors in drug-naïve mice. 
Morphine-dependent mice where withdrawal was not precipitated spent less time in the open 
arms compared to controls. Increased open-arm time was observed in morphine-dependent mice 
undergoing naloxone-precipitated withdrawal. The increase however was not due to an increase 
in locomotor activity because significant differences were not seen but morphine dependency 
was apparent given that there was not a significant increase in open-arm time for mice 
undergoing acute morphine withdrawal. Observed increase in open-arm duration was unexpected 
since opioid withdrawal is associated with anxiety. Furthermore, mice that underwent naloxone-
precipitated morphine withdrawal are known to be aversive and increase levels of corticosterone. 
The conclusions of this study were unexpected because of the unusual EPM behavior for mice 
undergoing naloxone-precipitated morphine withdrawal. As a result, researchers suggest that 
EPM behaviors observed raise the possibility that anxiety-behavior may be accompanied by 
withdrawal-induced behaviors as well in the EPM. 
In an attempt to characterize EPM behaviors during spontaneous and naloxone-
precipitated opiate withdrawal Shulteis, Yackey, Risbrough & Koob (1998) examined whether 
spontaneous and naloxone precipitated opiate withdrawal could be observed reliably in rats that 
were dependent on morphine.  Previous attempts with rats to model the anxiogenic-like effects of 
opiate withdrawal using the EPM has been found with mixed success. Rats were implanted with 
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morphine pellets and 72-hrs after implantation rats were tested in the EPM compared to control. 
One aspect of the study examined the effects when pellets were removed 8 or 12-hr prior 
exposure to the EPM. Anxiogenic effects, a reduction in time spent in the open arms was 
observed in opiate withdrawal in animals that had the pellets removed 8-hr prior but not in the 
12-hr prior the EPM. Researchers also examined naloxone-precipitated withdrawal and did not 
remove the pellets from the cages. Results showed that naloxone dose dependently precipitated a 
reduction in exploration of the open arms of the EPM. Overall these results suggest that both 
spontaneous and precipitated withdrawal from continuous morphine administration results in an 
anxiogenic-like effect in the plus-maze. 
 Peregud, Vorontsova, Yakovlev, Panchenko, & Gulyaeva (2008) demonstrated the 
involvement of nitric oxide (NO) in its mediating effects of opiates in opiate withdrawal. The 
study measured concentrations of the nitergic system and used the elevated plus-maze to 
measure anxiety during morphine withdrawal. During day six, after morphine withdrawal, rats 
showed more entries in the open arms of the EPM and also spent a longer time in the open arms. 
Correlations further showed that measure of the NO system in the hippocampus specifically and 
behavior of animals in the EPM, may represent one of the molecular mechanisms impairing the 
behavior of animals in abstinence. 
Hypocretins/Orexin Pathways 
Drug addiction is a chronic brain disease that has been found to have profound effects on 
the mesolimbic dopamine system and the release of corticotropin-releasing factor, however 
growing research has shown the importance of a different circuitry that innervates both systems 
during withdrawal. The orexins or hypocretins are a pair of neuropeptides that encode for a 
single precursor, as the endogenous ligands for two G protein coupled receptors that are 
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expressed in the brain and were previously considered to be orphan receptors (Chemelli et al. 
1999). An mRNA encoding the same neuropeptide precursor was independently identified by 
differential cloning approach and the putative encoded peptides were named as hypocretins. 
Orexin A and B are neuropeptides of 28-33 amino acids that are produced exclusively by 
neurons in lateral hypothalamus. 
Orexin peptides are unique among hypothalamic peptide neuromodulators that act 
directly at axon terminals and can increase the release of GABA and glutamate which both are 
responsible for almost all fast synaptic activity in the hypothalamus. The densest orexin 
projections are found in locus coeruleus, raphe nuclei, medullary reticular formation, 
paraventricular thalamic nucleus, septal nucleus and lamina of dorsal horn suggesting a possible 
role in modulating sensory input. Physiologic roles of orexin have been primarily focused on 
energy homeostasis because of past evidence of the lateral hypothalamus but based on 
neuroanatomical data, researchers have suggested a possible role of orexin as sleep wake 
modulators (Sakurai et al 1998).  
Although hypocretin/orexin (HRT/ORX) have been shown to have an essential role in 
sleep/wakefulness, other fundamental roles have recently been discovered that are not related to 
sleep. Orexin has been found to innervate important pathways such as neuroendocrine and 
autonomic function, appetite regulation, cardiovascular function and regulation of reproductive 
and stress hormone secretion (Samson, Taylor & Ferguson 2005). Orexin innervates several 
major ascending arousal pathways. A major input to the relay and reticular nuclei of the thalamus 
originates from cholinergic cell groups in the upper pons, pedunculopontine (PPT) and 
laterodorsal tegmental nuclei (LDT), which facilitate thalamocortical transmission. A second 
pathway activates the cerebral cortex to facilitate the processing inputs from the thalamus, which 
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comes from neurons in the monoaminergic cell groups, which include the tuberomammillary 
nucleus (TMN), the A10 cell group containing dopamine, dorsal and median raphe nuclei 
containing serotonin, and the locus coeruleus containing noradrenaline. The second pathway also 
receives input from the lateral hypothalamus containing orexin or melanin-concentrating 
hormone, and from the basal forebrain neurons containing GABA or Ach. Orexin also projects to 
the ventrolateral preoptic nucleus (VLPO), which includes the TMN, A10 cell group, raphe cell 
groups and the LC (Saper, Scammell & Lu 2005). 
 Orexin plays a unique role in autonomic function, researchers showed that hypothalamic 
and brain stem structures known to play a role in central cardiovascular regulation were 
innervated by ORX containing axon terminals and that the two receptors of ORX were localized 
at those sites (Sakurai et al. 1998; Ferguson & Samson 2003). Studies reported that when 
administration of exogenous orexin resulted in increased blood pressure and heart rate in 
conscious and anesthesized animals, with the effects mediated by activation of the sympathetic 
arm of the autonomic nervous system (Samson, Taylor & Ferguson 2005).  
Orexin is known to play a role alongside the endocrine system.  There are several studies 
showing the presence of ORX-positive axon terminals and receptors in hypothalamic and extra-
hypothalamic sites, which is recognized to be important in the control of anterior pituitary 
function of neuroendocrine effects of peptides (Samson, & Taylor & Ferguson 2005). Orexin has 
also been shown to have roles in appetite regulation where administration of ORX into the 
cerebroventricular system of conscious rats, regardless of fed state, did stimulate significant 
increases in food intake, however its effects are less than known neuropeptides to stimulate 
appetite like ghrelin or NPY (Samson, & Taylor & Ferguson 2005). Projections of ORX are 
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shown to end at the arcuate nucleus and administration at the arcuate nucleus increases NPY 
mRNA levels in the hypothalamus (Lopez, Seoane, Mdel, Dieguez & Senaris 2002).  
However, orexin does not appear to be a critical player in food intake behaviors but rather 
adapt the arousal and motivation levels for such behaviors to be carried out (Adamantidis & de 
Lecea 2008). Orexin has more significantly been shown to elicit a certain levels of arousal to 
engage exploratory and goal-oriented behaviors, which can ultimately strengthen over time and 
motivation for liquids and food, or more so lead to the reinstatement of a previously extinguished 
food seeking behavior in operant conditioning paradigms (Boutrel, Cannella & De Lecea 2010; 
Boutrel et al., 2005; Yamanaka et al. 2003).  
The basal forebrain cholinergic system plays a role in several functions of attention. 
Activation of the system from different afferent inputs is hypothesized to influence how 
attentional resources are distributed. Projections from the hypothalamus has been recognized as a 
key player and source of projections to the basal forebrain however, phenotypes of such inputs 
and conditions under the basal forebrain cholinergic system is unclear. Orexin has been shown to 
project to the basal forebrain with receptors on cholinergic parts of the basal forebrain affecting 
cell activity and cortical acetylcholine release. A study examining orexin inputs and the basal 
forebrain cholinergic system interactions concluded that dysfunction in orexin-acetylcholine may 
play a role in arousal and attentional deficits that accompany neurodegenerative conditions from 
drug addiction and age-related cognitive decline (Fadel & Burk 2009). 
Hypocretin/Orexin and Stress  
Not only has orexin been shown to activate key areas known for reward, recent evidence 
also suggests that orexins stimulate corticosterone release when injected in the brain ventricles, 
suggesting a role in the activation of the HPA axis (Stricker-Krongrad & Beck 2002). This 
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hypothesis has been supported with evidence that neuropeptide Y and corticotropin releasing-
hormone, are both involved in the feeding and release of corticosterone are closely interacting 
with orexin effects on food regulation (Ida et al. 2000). Data has also shown that corticotrophin-
releasing factor (CRF) peptidergic system directly innervates the hypocretin-expressing neurons. 
Several studies further show that the hypocretin cells also terminate to the CRF-system in order 
for feedback and the CRF activates the hypocretin system which relays the signal to brain stem 
nuclei involved in maintaining and activating arousal (Winsky-Sommerer, Boutrel & de Lecea 
2005). 
As described earlier, the hypothalamus-pituitary- adrenal axis is activated and the 
synthesis of the corticotrophin releasing factor (CRF) is induced in the paraventricular nucleus of 
the hypothalamus. The CRF stimulates the production of adrenocorticotropic hormone (ACTH). 
The release of ACTH then stimulates the release of glucocorticoids, which allows a feedback 
loop back to the hypothalamus (Koob & Le Moal 2000).  Orexin is known to play an important 
role in the “hyperarousal” state that characterizes stress and when hypocretin1 is centrally 
administered, the effects show an increase in plasma ACTH and corticosterone levels, similar to 
the central administration of CRF (Winsky-Sommerer, Boutrel & de Lecea 2005). The role of 
orexin as a mediator in the HPA axis is further supported when orexin receptors were found at 
each of the levels of the HPA axis (Blanco et al 2002; Lopez et al. 1999). In the behavioral 
“resident-intruder test” orexin knockout mice show a decrease in emotional responses to stress as 
well (Winsky-Sommerer, Boutrel & de Lecea 2005). 
The extent to which orexin projects to the HPA axis suggests that orexin neurons 
constitute a feedback circuit regulating arousal in response to stressful stimuli. Anatomical data 
between CRF and orexin showed that synapses between the two systems have the CRF 
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immunoreactive boutons and hypocretin immunopositive perikarya and dendrites in the lateral 
hypothalamus (Winsky-Sommerer, Boutrel & de Lecea 2005). Furthermore, hypocretin 
immunoreactive neurons express CRF 1 and 2 receptors, suggesting strong afferent innervation 
from the paraventricular nucleus, central nucleus of the amygdala, and bed nucleus of the stria 
terminalis (Winsky-Sommerer et al. 2004).  
Hypocretins are also considered regulators of allostasis with their greatest influences in 
basic homeostatic pressures like hunger, anxiety and drive for sex (Carter, Borg & de Lecea 
2009). In contrast to homeostasis, allostasis maintains stability levels outside the normal range 
and is achieved by varying the internal milieu to match the perceived and anticipated 
environmental demands (McEwen & Wingfield 2003; Robers, Heyser, Cole, Griffin & Koob 
2000). Under allostatic pressure, hypocretins have been shown to inhibit stress-induced 
depressive symptoms, reinstating homeostatic control of brain arousal (Carter, Borg & de Lecea 
2009). Furthermore, orexin has been implicated to mediate an allostatic generalized stress 
response to calorie restriction that allows an animal to overcome maladaptive depressive 
symptoms induced by chronic stress (Akiyama, Yuasa, Hayasaka, Horikawa, Sakurai & Shibata 
2004). Generally, orexin may not necessarily stimulate food intake, but activation of the orexin 
neurons mediate allostatic changes in behavior, for example in animals will be awake and 
motivated to obtain food during limited times when it is available (Carter, Borg & de Lecea 
2009). 
Hypocretin neurons are also reciprocally connected with neuropeptide Y (NPY) 
containing neurons, which are another peptidergic system, involved in acute stress (Heilig 2004). 
NPY and orexin have similar projections including extended amygdala, which is known to have 
an important role in responses to acute stress (Adrian et al. 1983; Baldo, Daniel, Berridge & 
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Kelley 2003). Also, when intracerebroventricular administration of NPY increases sedation, and 
has anxiolytic activity in response to some stimuli (Bannon et al. 2000), NPY was found to 
hyperpolarize hypocretin neurons in vitro (Fu, Acuna-Goycolea & van den Pol 2004). Thus, 
researchers have hypothesized that the behavioral effects of NPY are mediated by inhibition of 
the orexin system. The interacting circuits of CRF, orexin and NPY have sparked significant 
interest in multiple physiological and pathological situations, specifically in hyperaroused states 
associated with motivation and addiction. 
Hypocretin/Orexin and Addiction or Goal Oriented Behaviors 
One related aspect that the orexin system has had recent growing interest is the actions on 
arousal state and reward behaviors, specifically the mesolimbic dopamine neurons of the ventral 
tegmental area (Samson, Taylor & Ferguson 2005; Winsky-Sommerer, Boutrel & de Lecea 
2005) and its role in addiction and goal-oriented behaviors (Boutrel, Cannella & De Lecea 2010; 
Yamanaka et al 2003). Orexin is considered to play a critical role in regulation of drug-seeking 
and drug-taking behaviors as much as CRF, opioids, cannabinoids and nociception and has an 
excitatory effect on the VTA and inhibitory effect on the NAcc (Martin, Gabre, Siggins & De 
Lecea 2002). Microdialysis studies have shown that drugs of abuse increase extracellular levels 
of dopamine levels at the level of the NAc and neuroadaptations in the system is thought to 
underlie elements of addiction. The hypothalamic orexin system has been shown to interact with 
the mesocorticolimbic pathway, specifically the VTA (Carboni, Imperato, Perezzani & Di Chiara 
1989). Furthermore, the orexin projections that are found in the VTA have been localized with 
their terminals on tyrosine-hydroxylase positive cells with the VTA containing numerous orexin-
containing dense core vesicles and a high density of orexin receptors in the VTA and DA-
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containing and GABA-containing neurons (Korotkova, Sergeeva, Eriksson, Haas & Brown 
2003; Narita et al. 2006). 
One of the first studies demonstrating the link between orexin to drug addiction was a 
report on a decreased sign of precipitated opiate withdrawal displayed by mutant mice deficient 
in orexin (Gerogescu et al. 2003).  Another important discovery was the c-Fos activation of 
lateral hypothalamic orexin neurons correlated with preference for an environment paired with 
food and drug rewards. Reinstatement of an extinguished preference for an environment paired 
with natural and non-natural rewards was also observed when morphine was injected with orexin 
neurons being activated (Harris, Wimmer & Jones 2005). 
Fos activation in orexin neurons and the expression of conditioned place preference 
(CPP) for drug or natural rewards has shown strong correlations. Rats conditioned with 
morphine, cocaine or food in a CPP paradigm exhibit substantially increased Fos staining in LH 
orexin neurons on the drug- and food-free conditioned place preference test (Aston-Jones et al. 
2010). Self-administration studies have also shown Fos-activation in orexin neurons after 
exposure to ethanol-associated stimuli (Dayas, McGranahan, Martin-Fardon & Weiss 2008). 
Early studies showed that orexin projections include the midbrain dopamine (DA) neurons of the 
ventral tegmental area (VTA) (Baldo et al. 2003; Fadel & Deutch 2002; Peyron et al. 1998). 
Studies of drug reward and drug induced neuroadaptations have focused on orexin’s effects on 
the VTA and the mesocorticolimbic target regions such as the nucleus accumbens (NAc) and 
amygdala (Sharf, Sarhan & DiLeone 2010). 
Furthermore, the activation of orexin playing a role in reward-seeking and addiction 
neural circuitry has given new insights and investigation in determining whether the function or 
dysfunction of the orexin system may contribute to the overeating related to obesity (Sartor & 
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Aston-Jones 2010). In several studies, selective intake of high-fat food was induced by the 
injection of the mu opioid receptor agonist (DAMGO) into the nucleus accumbens core. 
Researchers concluded that orexin signaling in VTA is involved in DAMGO-induced intake of 
high-fat diet through a projection from NAc to hypothalamic orexin neurons (Stratford & Kelley 
1999; Baldo, Gual-Bonilla, Sijapati, Daniel, Landry & Kelley 2004). Also, previous findings 
showed that high-fat diet intake induced by inactivation of NAc shell caused an increase in Fos 
expression in LH and the intake decreased with NMDA antagonism in LH. Altogether, these 
studies suggest that a neural pathway linking the NAc and LH is involved in reward-based eating 
in sated rats (Cason et al. 2010). 
Hypocretin/Orexin and Stress & Drug Addiction 
The relationship between stress and addiction has been well established with the extended 
amygdala having a key role in mediating both positive and negative reinforcement associated 
with drug addiction (Kalivas & McFarland 2003; Koob 1999). The extended amygdala is 
composed of the medial subregion of the nucleus accumbens, bed nucleus of the stria terminalis 
and the central nucleus of the amygdala. These structures receive several afferent information 
from the limbic structures like the hippocampus, and basolateral amygdala, which then sends 
efferents not only to the medial part of the ventral pallidum but also the lateral hypothalamus. 
These connections, specifically the extended amygdala, provide a connection for the basal 
forebrain to the reward systems of the lateral hypothalamus through the medial forebrain bundle 
reward system (Koob 2000; Koob 1999). 
The orexin system has been shown to project to all of the major components of the 
extended amygdala, particularly the shell of the nucleus accumbens and the bed nucleus of the 
stria terminalis. Hypocretins have also been shown to be involved in GABAergic modulation of 
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the mesolimbic dopamine system, which provides anatomical and functional criteria for 
modulating critical connections regulation both positive and negative, reinforcing properties of 
drugs of abuse (Winsky-Sommerer, Boutrel & de Lecea 2005). Evidence shows that there is a 
close interaction between the CRF and hypocretin peptidergic systems (Ida et al. 2000; Winsky-
Sommerer et al. 2004) which places hypocretin neurons as a key system in the integration of 
emotional stimuli as well as in the integration of sensory inputs and suggests a role for this 
system in the stabilization of motivated behaviors. Hypocretin system has therefore been 
hypothesized to be a component that underlies vulnerability to relapse during a prolonged 
abstinence from drugs of abuse (Aston-Jones & Harris 2004). Furthermore, the orexin system 
may act as a cautionary alarm that prepares the organism for withdrawal and its consequences on 
energy homeostasis and allostasis (Winsky-Sommerer, Boutrel & de Lecea 2005). 
Studies have also shown that the orexin system also plays a role in the ability of 
conditioned stimuli to elicit cocaine-seeking behavior. In one study, rats were self-administered 
intravenous cocaine during a daily 2-hour session followed by extinction training in an operant 
chamber or abstinence in a home cage. After extinction, cocaine seeking was reinstated when 
distinct cues previously paired with cocaine infusions or re-exposure to the original self-
administration context. After abstinence, cocaine seeking was evaluated with an exposure again 
to the self-administration environment. Researchers found that cue-induced reinstatement of 
extinguished cocaine-seeking behavior was significantly attenuated by systemic administration 
of orexin antagonist, SB334867 (Smith, See & Aston-Jones 2009). 
Other studies examining ethanol intake and the orexin system have shown LH expressing 
orexin mRNA is increased after ethanol drinking in rats with an increase in Fos expression in 
orexin neurons following context-induced reinstatement of ethanol seeking (Dayas, 
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McGranahan, Martin-Fardon & Weiss 2008). A similar study investigated orexin system and its 
regulation of behavioral and biochemical processes underlying nicotine-induced anxiety like 
responses and reinstatement of nicotine-seeking behavior (Plaza-Zabala, Martin-Garcia, de 
Lecea, Maldonado & Berrendero 2010). Researchers found that with acute administration of 
nicotine induced anxiogenic-like effects were observed in the elevated plus-maze. Furthermore, 
pretreatment with OXR1-antagonist and in orexin knockout mice, anxiogenic-like effects of 
nicotine were blocked. Orexins were found to have an anxiogenic effect in acute administration 
of nicotine and behavioral responses were associated with activation of CRF and AVP neurons in 
the PVN that was dependent on orexin transmission. The study also supported the idea that 
activation of orexin can also reinstate nicotine-seeking behavior after induced withdrawal. 
To test whether orexin was involved in the acquisition of drug consumption Boutrel et al. 
2005 infused 0.2-1.5 nmol of ORX-1 into rat brains that were trained to self-administer cocaine. 
Researchers found no differences compared to the saline treated group or repeated injections of 
the peptide and different periods of the circadian cycle and at different exposure times to 
cocaine. It was concluded that hypocretins did no play a significant role in the consumption of 
cocaine, however when cocaine was given intracerebroventricularly, ORX-1 led to a dose related 
reinstatement of an extinguished cocaine seeking behavior. Supporting previously described 
studies, ORX-1 plays a significant role in reinstatement of cocaine seeking but mechanisms may 
be different from increased dopamine released (Harris, Wimmer & Jones 2005).  
Through recent evidence, it was hypothesized that the hypocretin and stress systems 
interact closely specifically in regulating drug-seeking behavior (Martin-Fardon, Zorrilla, 
Ciccocippo & Weiss 2010; Borgland, Ungless & Bonci 2010). This was shown by blocking the 
orexin-induced reinstatement of cocaine seeking by CRF/NA antagonism and to a lesser degree, 
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food-seeking behaviors also increased. In addition, antagonism of ORX-1 receptors blocked 
footshock-induced reinstatement of previously extinguished cocaine seeking. More importantly, 
ORX-1 significantly elevated intracranial self-stimulation (ICSS) thresholds in rats, reflecting a 
decrease in the activity of brain reward systems (Boutrel et al. 2005). The action of ORX-1 on 
ICSS thresholds is opposite to the well known threshold-lowering effects of cocaine, an index of 
cocaine-induced excitation of brain reward systems (Kenny, Koob & Markou 2003).  
Generally, research has shown a consistent trend that the orexin system is a new 
mechanism by which stress could influence relapse to drug seeking and drug taking from 
increased dopamine release (Martin-Fardon, Zorrilla, Ciccocioppo & Weiss 2010; Borgland, 
Ungless & Bonci 2010; Boutrel & de Lecea 2008; Bonci & Borgland 2009). ORX-1 is shown to 
reinstate cocaine seeking by mechanisms different from an increase of dopamine release and the 
blockade of ORX-1 induced reinstatement by CRF/noradrenergic antagonism suggests that 
orexin and stress systems may closely interact to regulate opiate seeking behaviors (Boutrel et al. 
2005). CRF has also been shown to induce glutamate release in the VTA of rats who have been 
exposed to cocaine but not in cocaine naïve rats (Wang, Shaham, Zitzman, Azari, Wise & You 
2005). Hypocretins have been shown to act synergistically with glutamatergic afferents to 
depolarize neurons in the VTA (Korotkova, Sergeeva, Eriksson, Haas & Brown 2003). 
Additionally, hypocretin has been shown to critically contribute to cocaine sensitization through 
the recruitment of NMDA receptors in the VTA.  
Altogether, these results suggest that hypocretins in concomitance with CRF could 
contribute to glutamate release facilitation that ultimately leads to the arousal/motivational 
systems activation including both adrenaline and noradrenaline. Chronic activation of these brain 
areas could lead to an allostatic state of brain reward systems that consequently underlies the 
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vulnerability to relapse for drug seeking after a period of protracted abstinence (Carter, Borg & 
de Lecea 2009). Furthermore, when the cessation of drugs of abuse does occur, the orexin system 
may act as an alarm signal that would prepare the organism for withdrawal and its consequences 
on energy and fluid homeostasis. Evidence has already shown that leptin, which hyperpolarizes 
orexin neurons also attenuates fasting-induced heroin-seeking behavior (Shalev, Morales, Hope, 
Yap, Shaham 2001) and mice deficient of orexin has diminished signs of precipitated opiate 
withdrawal (Georgescu et al. 2004). 
As discussed above, many studies have performed experiments in determining the 
specific effects of orexin in concomitance with CRF in drug addiction. In many studies, the 
activation of orexin was examined during the reinstatement of drug-seeking behavior or the 
overall role orexin may play in arousal during the drug addiction process. However, an 
insufficient number of studies have yet to observe drug-seeking behavior using the elevated plus-
maze during withdrawal, precipitated or spontaneous. The elevated plus-maze has been used 
extensively to study drug withdrawal, specifically in anxiety and drug-seeking behavior. In the 
present study, it is of interest to see the activity of orexin in rats that have been chronically 
exposed to morphine and then subjected to the elevated plus-maze. Furthermore, the purpose of 
the study was to assess the effects of chronically exposed rats to morphine and through 
spontaneous withdrawal, and exposure to the elevated plus-maze, to examine orexin and Fos 
activity of the lateral hypothalamus.  
Since morphine is known to exhibit both anxiolytic and anxiogenic effects depending on 
dosage, it was hypothesized that in rats that receive chronic morphine for seven days and who 
are then subjected to the elevated plus-maze should experience the anxiolytic effects of morphine 
and histologically have less orexin neurons active. Chronically exposed rats should also 
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behaviorally be less stressed compared to control. In rats that receive chronic morphine for six 
days and then do not receive morphine on the seventh day through induced-spontaneous 
withdrawal, should be more stressed and histologically have more orexin neurons activated and 
behaviorally may show, anxiogenic effects or drug-seeking behavior compared to the control. 
Methods 
 
Subjects 
 
Thirty-two male Sprague-Dawley rats (200-500g; 2-3 months old) were received from 
Charles River Laboratories (Wilmington, MA). The subjects were housed in groups of two in a 
humidity-temperature-controlled environment, with 12 hr light/dark cycles with free access to 
food and water. The rats were handled once three days prior to testing and once again on the day 
before testing. All procedures were approved by the Connecticut College Institutional Animal 
Care and Use of Laboratory Animals (National Research Council, 1996). 
Materials 
 EPM, morphine (Sigma-Aldrich), orexin and Fos antibodies (Santa Cruz biotechnology) 
Procedure 
 
Rats were weighed and recorded on the first day of injection and then every three days. 
Injections were given via the intraperitoneal (IP) route.   Rats were brought to the 
injection/testing room in groups of two in a plastic cage with rat shavings. After injection, the 
rats were held in the injection/testing room for 30 minutes and then brought back to the animal 
facility.  
Drug Conditions  
 
 Rats were randomly assigned in four different groups. Rats in Group 1M received 
3mg/kg of morphine for six days. On the seventh day, test day, the rats were administered 1 
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ml/kg saline. Rats in Group 2M received the same treatment as Group 1M except on test day 
received morphine. Rats in Group 3S received 3ml/kg of saline based on the weight of the rat for 
six days. On the seventh day, test day, the rats were not injected. Rats in Group 4S received the 
same treatment as Group 3S however, on test day the rats received saline. 
Stressor Exposure: Elevated-Plus Maze 
 
 Based on the subject’s group, 30 minutes after the injection, the rat was subjected to the 
elevated plus-maze (EPM). The elevated-plus maze exposure was conducted in an isolated room 
with dim lighting to minimize light disturbances. The EPM is a black plastic platform 50cm 
above ground, consisting of four arms arranged in a plus-sign, with two closed arms with walls 
(31 x 38cm) on all sides except the center, and two open arms with no walls. The same type arms 
are across from each other with a center square connecting all four arms. 
 Each arm was 10 x 38 cm long. On each EPM exposure the rat was individually placed 
on the EPM center platform facing the open arm. Each rat was left on the elevated plus-maze for 
5 minutes. A video camera was mounted above the maze to record and observe the behavior of 
the rats during the exposure. After each rat exposure, the EPM was cleaned with 50% ethanol 
solution to eliminate odor influences for the next animal. 
Anxiety Measures: Elevated-Plus Maze 
 
 All injections 3mg/kg IP morphine or saline were administered 30 minutes prior exposure 
to the EPM. Rats in Group 1M were given saline, Group 2M morphine, Group 3S no saline, and 
Group 4S saline. The elevated-plus maze exposure was as mentioned before. 
 Standard spatiotemporal measures of the numbers of entries onto, and the times spent on, 
open and closed arms were recorded. Entries were counted when all four paws were on the arm, 
and the time was counted in a particular arm until all four paws were off the arm. Drug-seeking 
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behavior was then measured by using the duration spent on the open-arms. Anxiolytic effects 
were also counted as the amount of time spent on the open arms 
In addition, the following behavioral measures, based on those previously reported by 
Fernandes and File (1996) were recorded: a) stretch attend posture; b) unprotected head dips. 
Stretch attend postures were defined as forward extensions of head and shoulders followed by 
retraction without stepping forward with hind paws. Unprotected head dips were defined as 
scanning over the side of the maze downward while on an open arm. 
Tissue Preparation 
 
 Rats were euthanized by exposure to a carbon dioxide chamber approximately an hour 
and a half after exposure to the elevated plus-maze. The rats were perfused transcardially with 50 
ml saline for 30 seconds followed by 400-500 ml of 4% paraformaldehyde in 0.1M phosphate 
buffer. The brains were extracted and post-fixed in 4% paraformaldehyde overnight and then 
transferred to a 30% sucrose solution. Coronal sections were taken at approximately 40μm and 
were obtained in a -20°C cryostat. The sections were stored in 4°C in cryoprotectant. 
Immunohistochemistry 
 
C-Fos 
 
 Two sections per animal from each subject were chosen to represent the lateral 
hypothalamus. Staining for C-Fos was conducted using avidin-biotin-horseradish peroxidase 
(ABC) method as described by Grahn et al. (1999). Sections were washed three times for 10 
minutes each in 0.01M phosphate buffered saline (PBS) prior to 24 hour incubation with a 1:800 
dilution of polyclonal rabbit anti-Fos primary antibody (Santa Cruz Lot #E2609) in a blocking 
solution composed of 1% normal goat serum, 1% bovine serum albumin, and 0.25% Triton-
X100 (30%), in 0.01 PBS. After the incubation the tissue was washed for 10 minutes in PBS and 
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then incubated for 2 hours in biotinylated goat anti-rabbit secondary antibody (Jackson 
Laboratories Lot #90982) diluted in 1:200 in blocking solution. 
After the incubation the sections were washed again three times, 10 minutes each in PBS 
and incubated for 2 hours with avidin-biotin complexed with horseradish peroxidase (Vectastain 
Elite ABC kit) in PBS. The sections were then washed three times for 10 minutes each in 0.1M 
PB and placed in a solution containing diaminobenzidine (DAB), cobalt chloride, ammonium 
chloride, nickel ammonium sulfate, and glucose oxidase in 0.1PB for 10 minutes. The reaction 
was started by the addition of β-D-glucose solution. The reaction was allowed to sit for 
approximately 15 minutes and then the tissue was placed in 0.01M PBS to end the reaction. The 
tissue was then subjected to orexin staining. 
Orexin  
 
The same sections used in c-Fos staining were then stained for orexin by using avidin-
biotin-horseradish peroxidase (ABC) method as described by Grahn et al. (1999). Sections were 
washed three times for 10 minutes each in 0.01M phosphate buffered saline (PBS) prior to 24 
hour incubation with a 1:100 dilution of polyclonal orexin anti-goat primary antibody (Santa 
Cruz Lot #C3110) in a blocking solution composed of 1% bovine serum albumin in 0.01 PBS at 
4°C . After the incubation the tissue was washed for 10 minutes in PBS and then incubated for 2 
hours in biotinylated donkey anti-goat secondary antibody (Jackson Laboratories Lot #93908) 
diluted in 1:200 in blocking solution. 
After the incubation the sections were washed again three times, 10 minutes each in PBS 
and incubated for 2 hours with avidin-biotin complexed with horseradish peroxidase (Vectastain 
Elite ABC kit) in PBS. The sections were then washed three times for 10 minutes each in 0.1M 
PB and placed in a solution containing diaminobenzidine (DAB) and glucose oxidase in 0.1PB 
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for 10 minutes. The reaction was started by the addition of β-D-glucose solution. The reaction 
was allowed to sit for about 15 minutes and then the tissue was placed in 0.01M PBS to end the 
reaction. The tissue was then washed with 0.01M PBS three times and mounted on slides that 
were allowed to dry for approximately 24 hours. The slides were then dehydrated in a series of 
alcohols and defatted with Histoclear. The slides were coverslipped with Permount. 
Image Analysis 
 
 An observer blind to the conditions of the rats analyzed the sections. Each of the sections 
of the lateral hypothalamus for each rat was assessed for the number of Fos-stained nuclei, 
orexin stained nuclei, and double-labeled orexin and Fos-stained nuclei. Ovoid particles that 
were black were counted as Fos-stained nuclei. Ovoid particles that were brown were counted as 
orexin-stained cells and particles that were brown and black were counted as double-labeled.  
 Two sections were chosen to represent the lateral hypothalamus (LH) and both sides of 
the LH were counted. The LH was comparable to that illustrated by Paxinos and Watson (1998) 
at the anterior-posterior coordinate of 6.44 mm from interaural zero. The area encompassing the 
LH was estimated using the top of the third ventricle and the optic tract. Particles were counted 
just medial to the optic tract in an area estimated a little less than one half of the total area 
between the third ventricle and the optic tract. The LH area was defined by using the same circle-
defined shape across all sections. 
Statistical Analysis 
 
Behavioral statistical analyses were performed using SPSS 11.0 for Windows 2000 
Professional. A one-way analysis of variance (ANOVA) was performed for each behavioral 
measure; stretch-attend postures, head dips and open arm duration as the dependent variable, 
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with the different conditions as the independent variable. A Post-Hoc analysis (Tukey) revealed 
specific between group differences. 
A one-way analysis of variance (ANOVA) was performed for the number of closed 
entries as the dependent variable, with the different conditions as the independent variable. A 
Post-Hoc analysis (Tukey) revealed specific between group differences. 
A one-way analysis of variance (ANOVA) was performed for the LH the number of Fos-
stained nuclei as the dependent variable, with the different conditions as the independent 
variable. A Post-Hoc analysis (Tukey) revealed specific between group differences. 
 A one-way analysis of variance (ANOVA) was performed for the LH analyzing the 
number of double-labeled nuclei as the dependent variable, with the different conditions as the 
independent variable. A Post Hoc analysis (Tukey) revealed specific between group differences. 
The level of significance was defined as p<0.05 in all experiments.  
Results 
 
 It was hypothesized that rats that received chronic morphine for seven days and then 
subjected to the elevated plus-maze (2M) would spend more time on the open-arms, an 
anxiolytic effect. Rats who received chronic morphine for six days and then underwent 
spontaneous induced-withdrawal anxiety on the seventh day (1M) were expected to exhibit drug-
seeking behavior by spending more time on the open arm (Mantsch, Baker, Francis, Katz, Hoks 
& Serge 2007). A one-way ANOVA was conducted for all test groups 1M, 2M, 3S and 4S for 
open-arm duration. No significant findings were observed. Interestingly, although not significant, 
the mean open-arm duration for the 1M group was less than the 2M (Figure 1). This trend shows 
that spontaneous-induced withdrawal from morphine in rats, may produce more anxiogenic 
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effects rather than drug seeking behavior which would be defined as more time spent in the open 
arms. 
 Other behavioral measurements such as closed entries, stretch-attend postures, and 
unprotected head dips on the elevated plus-maze were also scored like number of closed entries, 
stretch-attend postures and unprotected head dips. One-way ANOVAs were conducted for all 
test groups 1M, 2M, 3S and 4S for the other behavioral measurements. No significant findings 
were observed in number of closed entries (Figure 2) stretch attend postures (Figure 3) or 
unprotected head dips (Figure 4).  
 Cells were double labeled for Fos activation and orexin expression (Figure 5, 6). A one-
way between subjects ANOVA was conducted to compare the effect of morphine on the number 
of double-labeled cells in rats that have been chronically administered morphine for seven days 
and rats who have chronically received morphine for six days and then underwent spontaneous-
induced withdrawal anxiety conditions using the elevated plus-maze.   
There was a significant main effect of morphine on the number of double-labeled cells on 
the test groups at p<0.05 level for the four conditions [F (3, 26) = 4.664, p = 0.010] (Figure 7; 
supplementary images of c-Fos and orexin labeled Figure 7b, c). Post hoc comparisons using the 
Tukey HSD test indicated that the mean score for rats who did received chronic morphine and 
morphine on test day (M = 0.4063, SD = 0.3764 was significantly different than the rats who 
received chronic morphine and then saline on test day (M = 0.7813, SD = 0.7727), compared to 
control who did not receive an injection (M = 0.0625, SD = 0.1767) and the control saline group 
(M = 0.000, SD = 0.000). This result demonstrates that Fos cell activation, specifically in the LH 
of orexinergic neurons was greater in rats that were chronically administered morphine and then 
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received saline after induced spontaneous withdrawal compared to rats who received chronic 
morphine and control. 
Discussion 
Drug addiction is a chronic brain disease that has been found to have profound effects on 
the mesolimbic dopamine system and the release of corticotropin-releasing factor. Research has 
shown the importance of a different circuitry that innervates both systems during withdrawal. 
Orexin is considered a major player in the regulation of drug-seeking and drug-taking behaviors 
as much as other peptide systems like CRF, opioids and cannabinoids (Boutrel, Cannella & de 
Lecea 2010). Early evidence linking orexin to drug addiction was a report on a decrease in signs 
of opiate withdrawal of orexin knockout mice (Georgescu et al. 2003). Studies have also shown 
that Fos expression in the LH occurs in orexin neurons projecting to the ventral tegmental area 
(VTA). Furthermore, Fos activation increased with elevated morphine preference during 
protracted withdrawal than non-VTA-projecting orexin neurons. This result indicates that the 
VTA is an important site of action for orexin’s role in reward processing. Orexin has also been 
shown to reinstate extinguished morphine and cocaine drug-seeking behavior.  
Overall, LH orexin neurons have been described as an important input to the VTA for 
behavioral effects associated with reward-paired stimuli in animals, specifically in observing 
drug addiction. There has been extensive literature on the relationship between orexin in arousal 
and stress and the effects of orexin during drug addiction and reward seeking. Specifically, 
research has focused on paradigms using conditioned-place preference (CPP) and intracranial 
administration of ORX1 in areas of the brain like HPA axis, NAcc, VTA, LH and other neural 
projections of the orexin system. However, there has not been much exploration of orexin 
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activation in rats that have been chronically exposed to morphine and then observed during 
spontaneous withdrawal on the elevated plus-maze.  
The elevated plus-maze (EPM) has been used to study anxiety-related behavior in rodents 
and assessing the anti-anxiety effects of pharmacological agents and steroid hormones (Pellow, 
Chopin, File & Brilley 1985), defining brain regions and mechanisms underlying anxiety-related 
behavior (Pellow, Chopin, File & Brilley 1985; Hogg 1996; Walf & Frye 2007). Activity in the 
open arms is considered to be a conflict between the rodent’s preference for protected areas or 
closed arms and their innate motivation to explore novel environments. Ethological measures are 
observed like the number of rears, head dips, freezing or stretched-attend postures (Rodgers & 
Johnson 1995). Normal exploratory behavior in the elevated plus maze usually favors the closed 
arms and this tendency to stay in the closed aspects of the maze can be enhanced by drugs, like 
anxiogenics that increase the aversion towards the anxiety-provoking open arms. In contrast, 
when subjects are administered anxiolytic compounds, this will reduce the natural aversion to the 
open arms and promote exploration.  
The critical aspect of the EPM is the number of entries made onto the open arm and time 
spent on the arms. These variables have been correlated with anxiety (Hogg 1996). Locomotor 
activity is assessed by monitoring the number of total open arm entries or closed arm entries. 
(File 1992; Lister 1987). The elevated plus-maze has frequently been used in research as a tool to 
measure anxiety-like behaviors during withdrawal. Subjects who have been repeatedly exposed 
to drugs of abuse are hypothesized to exhibit withdrawal-like symptoms like drug-seeking 
behavior. Drug-seeking behavior has been generally characterized as the subject more likely 
spending time in the closed arms compared to the open arms in the elevated plus maze. However, 
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other researchers have also defined drug-seeking behavior as more time in the open arms in the 
EPM as well.  
Studies have been able to show the relationship between discrete or contextual cues of 
previous drug taking and relapse, however the role that drug-withdrawal cues play in relapse has 
not been successfully determined. Conditioned place preference (CPP) is an animal model used 
to study the influence of drug-associated stimuli on drug seeking (Bardo and Bevins 2000; 
Hoffman 1989). CPP paradigm has been a valid measure of characterizing the different stages of 
drug addiction. Drug-induced conditioned place preference explores the reinforcing effects of 
drugs of abuse. A distinctive environment is paired repeatedly with administration of a drug and 
a different environment is repeatedly paired with administration of a vehicle (Bardo & Bevins 
2000).  
CPP occurs when repeated administration of a drug is paired to an environment and 
results in the ability of the environment to elicit approach behavior and increased time in the 
absence of the previously administered drug. This phenomenon is considered as an example of 
dopamine-mediated incentive learning and that increased time spent by animals in a drug-paired 
environment can be considered as a measure of drug-seeking behavior and reinforcing effects of 
drugs (Bardo and Bevins 2000; Le Foll and Goldberg 2009). CPP has been demonstrated for 
most drugs of abuse, as well as for natural reinforcers such as food. The acquisition of a drug-
induced CPP is likely to be correlated with other reinforcing effects of abused drugs, whereas its 
expression reflects the influence on behavior of environmental stimuli previously associated with 
a drug’s effects (Le Foll & Goldberg 2009). Recent place conditioning studies in rats 
demonstrate that extinguished CPP can be reinstated by injections of the conditioning drug 
(Mueller, Perdikaris & Stewart 2002) or stress (Mueller and Stewart 2000). Thus the 
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reinstatement of CPP in the animal model may provide a simple, noninvasive and rapid 
procedure for investigating the mechanisms for drug relapse compared to the EPM 
characterization of drug-seeking.  
In order to detect the neural activity of orexin during spontaneous withdrawal, rats were 
chronically administered morphine for six days, then taken off morphine the seventh day and 
subjected to the elevated plus-maze. Behavioral measurements were taken during the five 
minutes on the EPM and then compared to morphine chronically exposed rats of seven days and 
control. It was hypothesized that rats undergoing spontaneous induced withdrawal would 
experience anxiogenic effects similar to Buckman, Hodgson, Hofford and Eitan (2009) who 
reported in mice undergoing both naloxone-precipitated and spontaneous opioid withdrawal 
exhibited an unexpected outcome where there was an increase time and entries on the EPM on 
the open arm compared to controls. However, other studies examining cocaine withdrawal, 
demonstrated that rats that are exposed to chronic administration of cocaine and then one-day 
withdrawal found an increase in anxiety-like behavior, using the elevated plus-maze (Perrine, 
Sheikh, Nwaneshiudu, Schroeder and Unterwald 2008).  
The present study defined drug-seeking behavior similar to Buckman, Hodgson, Hofford 
and Eitan (2009), as having a longer duration on the open arm of the EPM. This was 
hypothesized because of the conditioned-environmental cues as mentioned in the methods; 
where rats were brought to the testing/holding room at the same time and the same procedural 
process was done before and after injections. Drug-associated stimuli or “cues” elicit a craving 
for drugs of abuse as a consequence of repeated pairing with drug use (Childress et al. 1999; See 
2002). Cues are hypothesized to motivate drug-seeking behavior and subsequent relapse in 
abstinent individuals (Childress, Mclellan & O’Brien 1986; See 2002; Sinha, Fuse, Aubin, 
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O’Malley 2000). Conditioning of the procedural process and environmental cues employed in 
the present study was hypothesized to influence withdrawal-like symptoms. Specifically during 
an anxiety environment with cues associated with drug withdrawal symptoms that occur when 
the drug is not available.  
Rats who were administered chronic morphine for seven days and then subjected to the 
EPM were observed. It was hypothesized that compared to the spontaneous withdrawal group, 
rats chronically exposed to morphine would exhibit an anxiolytic effect dependent on the dose of 
morphine by spending more time on the open arms.  However, the neural activity of chronically 
exposed rats to morphine would not show, or show fewer orexin activated cells in the lateral 
hypothalamus compared to the spontaneous induced-withdrawal group and control group.  
Interestingly, although not significant, the mean open arm duration of spontaneous 
withdrawal rats was lower (89.24s, n=8) than the chronically morphine exposed rats (121.16s, 
n=8). This was surprising because the literature has suggested that during cocaine and morphine 
withdrawal, open arm duration increases because of the anxiolytic effects of the substances. 
There was however, a significant difference in the number of Fos-orexin activated cells in the 
lateral hypothalamus which may suggest that although the rats undergoing spontaneous 
withdrawal did not exhibit the drug-seeking behavior as defined, rats were experiencing an 
anxiogenic effect by spending more time in the closed arms of the EPM. This observation 
follows the general acceptance in EPM literature that an anxiogenic effect suggests more time 
spent in the closed arms. Drug-seeking behavior, particularly when using the EPM during drug-
withdrawal needs to be defined and accepted throughout the literature. Researchers need to come 
to a conclusion in what defines drug-seeking behavior and possibly make further behavioral 
measurements of what entails such behavior in addition to open arm time duration. This 
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discrepancy makes it difficult to interpret the data from the present study because the mean open 
arm duration of the spontaneous withdrawal rats can be interpreted as drug-seeking behavior or 
not.  
Alternative measures like using the CPP might give a better indication of drug-seeking 
behavior because of supporting evidence that an increase in the amount of time the animal 
spends in the drug-paired environment indicates that the drug-associated contextual stimuli has 
acquired secondary or conditioned incentive properties, presumably via pairing with the 
rewarding effects of the drug (See 2002; Hoffman 1989). Pairing the EPM and CPP might give a 
better indication of withdrawal-like symptoms associated with anxiety, and the CPP may give 
more information of drug-seeking behavior associated with contextual cues of addiction. Using a 
place preference relapse model, researchers found that while spontaneous withdrawal and 
naloxone-precipitated withdrawal did not effectively reinstate extinguished morphine place 
preference, morphine-withdrawal cues significantly reinstated the morphine CPP. Moreover, 
activation of the CRF receptor is involved in reinstatement of drug-seeking behavior induced by 
conditioned withdrawal (Lu et al. 2005). 
The number of closed arm entries was also observed to see if there was significance in 
preference of the closed entries of rats undergoing withdrawal and rats with chronic exposure to 
morphine. Furthermore, the number of closed entries was hypothesized to see if drug-seeking 
behavior could be established in this context. No significant findings were observed. However, 
interestingly the number of closed entries was similar as shown in Figure 4. Rats that were 
chronically administered morphine and then subjected to spontaneous withdrawal did have the 
fewest number of entries (3.63), compared to the total mean for four groups, which were 4.10. 
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The number of closed entries could be used as a behavioral measurement of drug-seeking if the 
definition of drug-seeking is more time spent in the closed arms of the EPM. 
The significant finding of double-labeled Fos-orexin activated cells supports some of the 
behavioral effects during induced withdrawal. This result demonstrates that double-labeled Fox-
orexin activation in the LH was greater in rats undergoing spontaneous withdrawal compared to 
rats that had chronic exposure to morphine and control. This suggests, that during induced 
spontaneous withdrawal, orexin neurons are activated when the subject is subjected to the 
elevated plus-maze compared to control. This finding supports the literature that orexin neurons 
are activated during morphine withdrawal, specifically when the subject is placed in an anxiety-
induced environment. Further studies need to be done in other brain areas that the orexin neurons 
project to that include the brain’s reward circuitry; the dopamine mesolimbic dopamine systems 
and also the stress activated areas of the brain including the HPA axis and the extended 
amygdala in order to determine the role of orexin during withdrawal.  
Studies examining the effect of orexin in regulating the anxiogenic-like effects of 
nicotine found that the administration of SB334867 blocked the effects of OXR1. The antagonist 
SB334867 also prevented the activation of CRF and arginine-vasopressin (AVP) neurons, which 
also expressed OXR1 (Plaza-Zabala, Martin-Garcia, de Lecea, Maldonado & Berrendero 2010). 
Another study examining morphine place preference used the OXR1 antagonist SB334867 to 
observe behavior after morphine-induced behavioral sensitization. Researchers found that OXR1 
antagonist prior to CPP did not significantly differ from wild-type controls in locomotor activity 
following acute or chronic morphine treatments. In contrast, orexin-knockout mice did not differ 
from wild-type controls in preference for a morphine-paired environment, SB334867 
significantly attenuated place preference for morphine but not a cocaine-paired environment 
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(Sharf, Guarnieri, Taylor & DiLeone 2010). Aston-Jones et al. (2010) examined the OXR1 
receptor antagonist SB334867 in self-administration studies where administration of the 
antagonist blocked cocaine-seeking induced by discrete or contextual cues previously associated 
with cocaine, but not by priming injection of cocaine. Furthermore, there were no observable 
effects of OXR1 antagonist on self administration, suggesting that orexin antagonist does not 
play a role in the reinforcing properties. 
Systemic administration of the OXR1 antagonist before CPP significantly attenuates the 
expression of morphine preference indicating that activation of the LH orexin neuron plays a role 
in driving the associated preference (Aston-Jones et al. 2010). In order to determine if 
conditioned activation of orexin neurons is also involved in driving the reinstatement of 
extinguished drug-seeking, rats were conditioned to morphine CPP then underwent extinction of 
morphine preference by repeatedly exposing them to the CPP environment without drug reward. 
When extinction was established, the Y4 receptor agonist rat pancreatic polypeptide (rPP) 
stimulated Fos induction in orexin neurons when injected into the LH. rPP microinjected into the 
LH also produced a reinstatement of preference in the morphine CPP (Harris et al. 2005). The 
reinstatement with LH rPP was further found to be specific for orexin neurotransmission because 
it completely blocked systemic pretreatment with SB334867. Intracerebroventricular 
administration of ORX1 was also found to reinstate extinguished cocaine seeking responses in a 
self-administration paradigm, further suggesting that orexin can drive drug-seeking and relapse 
(Boutrel et al. 2005).  
Other reports have demonstrated that SB334867 decreases both alcohol and nicotine self-
administration behaviors (Hollander, Lu, Cameron, Kamenecka & Kenny 2008) compared to 
administration of ORX directly into the PVN or in the LH which increases ethanol-drinking in 
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rats without affecting food and water intake (Schneider et al. 2007). Also, blocking the orexin 
system prevents cue-induced reinstatement of previously extinguished alcohol-drinking behavior 
(Hollander, Lu, Cameron, Kamenecka & Kenny 2008; Lawrence, Cowen, Yang, Chen & 
Oldfield 2006). Impact of orexin and opiate intake has not been extensively studied but 
observations have been made demonstrating a role of orexin in mediating the expression of 
precipitated morphine withdrawal (Georgescu et al. 2003) as well has aversion for a 
compartment previously paired with morphine administration in orexin-deficient mice. This 
suggests that orexin regulates opiate seeking and taking behaviors. Taken together, the 
administration of ORX1 blockade has been suggested as a drug target in preventing relapse for 
alcohol, morphine and nicotine seeking (Lawrence, Cowen, Yang, Chen & Oldfield 2006; 
Harris, Wimmer & Jones 2005). 
Originally, the study had a larger experimental design that included the use the ORX1 
antagonist, SB334867. Two more groups (and control) would have been added to the design 
where rats would be chronically administered morphine for six days and then on the seventh day 
would not be given morphine but the ORX1 antagonist, SB334867, then subjected to the EPM. 
The second group would be chronically administered morphine for seven days and also the 
OXR1 antagonist, SB334867, and then subjected to the EPM. Rats undergoing spontaneous 
withdrawal and then administered ORX1 antagonist SB334867 on the seventh day instead of 
morphine would not exhibit drug-seeking behavior as described in the study compared to rats 
who were exposed to chronic morphine and underwent spontaneous withdrawal. Furthermore, 
orexin neurons would not be active in the LH. Rats chronically exposed to morphine and then 
received the OXR1 antagonist SB334867 is hypothesized to behave similar to control where the 
anxiolytic effects of the morphine are blocked so anxiolytic-like behavior would be attenuated 
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(Cason et al. 2010). The addition of these two groups and their controls would further help 
characterize the role and activation of orexin during spontaneous withdrawal and anxiety.  
There were several factors that challenged the results of the current study. For one, time 
constraints caused the number of brain areas of interest to be limited to only observing the lateral 
hypothalamus, leaving the VTA and NAcc for future investigation. Although there was care in 
preventing inconsistency in the quantification of Fos-activated, orexin-activated and double-
labeled activated cells, it is possible that some background staining may have been counted as a 
positive signal. This would cause higher variability between samples, disguising effects of 
orexin-activated cells. A certain threshold was used to account for orexin-activated cells but this 
was used at the counter’s own discrepancy. Another factor that could have affected the results 
was the scoring of the behavioral measurements. Again, due to time constraints, behavioral 
scoring would have been stronger if there were a blind-scorer to the study. Overall, the main 
factor that challenged the present study was the time constraint and the ultimate goal of the 
study. Time was used as wisely as possible, therefore parts of the study had to be cut out as 
described above. 
There was a statistically significant difference in Fos-orexin double-labeled cells between 
groups, which suggests that orexinergic neurons were activated during spontaneous withdrawal 
from morphine after being subjected to the elevated plus-maze (EPM). There were no other 
significant differences found, however general trends like the mean number of orexin-activated 
cells and open-arm duration were interesting insofar that if the experimental design expanded to 
the use of the OXR antagonist, SB334867, other observations or conclusions could be made. 
Also the original study was going to examine dopaminergic mesolimbic areas of the brain, and 
stress activated areas however, this was unachievable due to time constraints. If the study was to 
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be repeated areas like the VTA, NAcc, extended amygdala and measures of CRF would be 
measured and analyzed. The activation of the orexin neurons in the LH shows that there’s a 
relationship between withdrawal and anxiety; furthermore the significance indicates that this 
needs to be further examined and by observing the areas as mentioned before, this would help in 
determining the orexin’s mediating effects of arousal during withdrawal. 
As far as we know, there is not an extensive amount of literature of studying the role of 
orexin during spontaneous morphine withdrawal, particularly by using the elevated plus-maze to 
measure drug-seeking behavior and anxiety. The present study was the first to observe orexin 
during spontaneous morphine withdrawal by using the elevated plus-maze. The present study 
also attempted to characterize drug-seeking behavior that may be characterize better in CPP 
instead of the EPM. However, coordinating the use of both CPP and EPM in observing drug 
withdrawal may give insight into the anxiety-like behaviors and drug-seeking behaviors that are 
associated with addiction with drugs of abuse. Future studies in using the elevated-plus maze, 
and orexin should be implemented in the growing research in orexin and drug addiction and 
stress.  
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Table 1. Experimental drug design across all groups, each group was given 3mg/kg of morphine 
or saline solution based on weight and depending on each group. Every three days, which are 
labeled *, indicate days where the subjects were weighed, M = morphine, and S = saline. On test 
day, the rats were exposed to the elevated plus-maze for five minutes and behavioral 
measurements were taken. n=8 per group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 1 Day 2 Day 3* Day 4 Day 5 Day 6* Day 7: EPM 
Chronic Morphine 
       1M : Green M M M M M M S 
2M : Blue M M M M M M M 
Chronic Saline 
       3S : Orange S S S S S S No Injection 
4S : Yellow S S S S S S S 
ORX and EPM   78	  
Figure Captions 
 
 
Figure 1.  The mean open-arm duration to the EPM in rats in each group on Day 7, where 1M 
received saline, 2M received morphine, 3S received no injection and 4S received saline.  
 
Figure 2. The mean number of stretch attend postures during exposure to the EPM on Day 7, 
where 1M received saline, 2M received morphine, 3S received no injection and 4S received 
saline. 
 
Figure 3. The mean number of unprotected head dips during exposure to the EPM on Day 7, 
where 1M received saline, 2M received morphine, 3S received no injection and 4S received 
saline. 
 
Figure 4. The mean number of closed entries during exposure to the EPM on Day 7, where 1M 
received saline, 2M received morphine, 3S received no injection and 4S received saline.  
 
Figure 5. The mean number of c-Fos cell activation of both right and left sides of the lateral 
hypothalamus (LH) of rats after subjected to the EPM on Day 7. Two pieces of stained tissue 
were used per rat.  
 
Figure 6. The mean number of double-labeled c-Fos and orexin, cell activation of both right and 
left sides of the lateral hypothalamus (LH) of rats after subjected to the EPM on Day 7. Two 
pieces of stained tissue were used per rat.  
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Figure 7. An example of a double-labeled c-Fos/orexin activated cell in the lateral hypothalamus 
(LH) of rats after subjected to the EPM on Day 7.  
 
Supplementary Figure Captions 
 
Figure 7b. An example of a C-Fos activated cell in the lateral hypothalamus (LH) of rats after 
subjected to the EPM on Day 7.  
 
Figure 7c. An example of a orexin labeled cell in the lateral hypothalamus (LH) of rats after 
subjected to the EPM on Day 7.  
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Figure 7b. 
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Figure 7c. 
 
 
 
	  
